Drug Trial Radar · NCT07156578
A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
25
Planned (sponsor's estimate)
Start
Nov 10, 2025
Primary completion
Apr 15, 2028
Study completion Apr 15, 2028
Sponsor
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.
Conditions
- Hypothalamic Obesity
Interventions
BivamelagonDrug
daily dose of oral bivamelagon
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of bivamelagon as assessed by the number and frequency of AEsTime frame: Baseline to up to 2 years
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado
University of Iowa Children's Hospital
Iowa City, Iowa
Tufts Medical Center
Boston, Massachusetts
Columbia University
New York, New York
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
St. Jude Children's Research Hospital
Memphis, Tennessee
Birmingham Women's and Children's NHS Foundation Trust
Birmingham, United Kingdom
University of Cambridge
Cambridge, United Kingdom
Great Ormond Street Hospital for Children
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.